Hot Features
프리미엄
Design Therapeutics Inc (DSGN)
NASDAQ
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.74 | -13.4790528233 | 5.49 | 5.615 | 4.51 | 227060 | 5.04402019 | CS |
| 4 | 0.0573 | 1.22104545358 | 4.6927 | 6.91 | 4.5 | 444579 | 5.52997237 | CS |
| 12 | 0.43 | 9.9537037037 | 4.32 | 6.91 | 3.93 | 274255 | 5.13402161 | CS |
| 26 | 1.05 | 28.3783783784 | 3.7 | 6.91 | 3.15 | 254802 | 4.56072478 | CS |
| 52 | 2.47 | 108.333333333 | 2.28 | 6.91 | 1.96 | 297670 | 3.39588086 | CS |
| 156 | -10.18 | -68.1848626926 | 14.93 | 26.3 | 1.94 | 347928 | 7.4294917 | CS |
| 260 | -23.25 | -83.0357142857 | 28 | 50 | 1.94 | 316726 | 8.52339609 | CS |
